Boston Scientific Co. (NYSE:BSX) Shares Bought by Capital Analysts LLC

Capital Analysts LLC grew its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 2.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 41,211 shares of the medical equipment provider’s stock after purchasing an additional 868 shares during the period. Capital Analysts LLC’s holdings in Boston Scientific were worth $2,382,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Bruce G. Allen Investments LLC acquired a new stake in shares of Boston Scientific in the 4th quarter worth about $28,000. Venturi Wealth Management LLC increased its holdings in shares of Boston Scientific by 58.0% in the 4th quarter. Venturi Wealth Management LLC now owns 586 shares of the medical equipment provider’s stock worth $34,000 after acquiring an additional 215 shares during the period. Coppell Advisory Solutions LLC acquired a new stake in shares of Boston Scientific in the 2nd quarter worth about $34,000. Motco increased its holdings in shares of Boston Scientific by 136.3% in the 3rd quarter. Motco now owns 645 shares of the medical equipment provider’s stock worth $34,000 after acquiring an additional 372 shares during the period. Finally, Sunbelt Securities Inc. acquired a new stake in shares of Boston Scientific in the 1st quarter worth about $32,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Stock Up 0.2 %

Shares of NYSE BSX traded up $0.12 during mid-day trading on Tuesday, reaching $67.56. The company had a trading volume of 594,924 shares, compared to its average volume of 6,290,462. The stock has a fifty day moving average of $67.05 and a two-hundred day moving average of $59.52. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.82 and a current ratio of 1.32. The company has a market capitalization of $99.12 billion, a price-to-earnings ratio of 63.03, a PEG ratio of 2.38 and a beta of 0.78. Boston Scientific Co. has a 12-month low of $48.35 and a 12-month high of $69.21.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, January 31st. The medical equipment provider reported $0.55 earnings per share for the quarter, beating the consensus estimate of $0.51 by $0.04. The firm had revenue of $3.73 billion for the quarter, compared to analyst estimates of $3.59 billion. Boston Scientific had a net margin of 11.19% and a return on equity of 15.99%. During the same quarter last year, the firm earned $0.45 earnings per share. As a group, equities research analysts expect that Boston Scientific Co. will post 2.25 EPS for the current year.

Insider Activity at Boston Scientific

In related news, CFO Daniel J. Brennan sold 13,662 shares of the firm’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $65.86, for a total transaction of $899,779.32. Following the transaction, the chief financial officer now owns 271,542 shares of the company’s stock, valued at $17,883,756.12. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, CFO Daniel J. Brennan sold 13,662 shares of Boston Scientific stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $65.86, for a total value of $899,779.32. Following the transaction, the chief financial officer now owns 271,542 shares of the company’s stock, valued at $17,883,756.12. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Edward J. Ludwig sold 7,000 shares of Boston Scientific stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $65.03, for a total transaction of $455,210.00. Following the completion of the transaction, the director now directly owns 41,374 shares in the company, valued at approximately $2,690,551.22. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 50,979 shares of company stock valued at $3,418,529. 0.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on BSX shares. JPMorgan Chase & Co. increased their price objective on shares of Boston Scientific from $60.00 to $72.00 and gave the stock an “overweight” rating in a report on Thursday, February 1st. Truist Financial raised their target price on shares of Boston Scientific from $59.00 to $66.00 and gave the company a “buy” rating in a research note on Friday, December 22nd. Citigroup raised their target price on shares of Boston Scientific from $71.00 to $79.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Argus raised their target price on shares of Boston Scientific from $69.00 to $80.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Finally, BTIG Research reissued a “buy” rating and set a $64.00 target price on shares of Boston Scientific in a research note on Friday, December 29th. Two research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Boston Scientific currently has a consensus rating of “Moderate Buy” and an average target price of $68.50.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.